GlassScriptPhysician profile
Dionne A Brown
NPI 1831698554
$3,350.95
in general payments reported to CMS, 2019-2025
23 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,358 · 2022: $1,395 · 2023: $404 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $597.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,274.19 | 2021-2023 | |
| Celgene Corporation | $249.23 | 2021-2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $239.29 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $216.67 | 2021-2023 | Dificid |
| Gilead Sciences, INC. | $201.15 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $147.38 | 2021-2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.78 | 2021-2022 | |
| Janssen Biotech, INC. | $125.11 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $106.58 | 2022-2023 | Dupixent |
| Ferring Pharmaceuticals INC. | $100.30 | 2021-2022 | |
| Redhill Biopharma INC. | $84.75 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.15 | 2021-2022 | |
| Indivior INC. | $75.68 | 2025 | Sublocade |
| Pfizer INC. | $74.17 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $45.51 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $40.71 | 2022 | |
| Braeburn INC. | $35.07 | 2025 | Brixadi |
| Ardelyx, INC. | $22.30 | 2022 | |
| Orexo US, INC. | $21.98 | 2025 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $20.73 | 2022 | |
| Axsome Therapeutics, INC. | $16.19 | 2025 | Auvelity |
| Horizon Therapeutics Plc | $15.55 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dionne Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.